Vanguard Group’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.27B | Sell |
2,261,848
-21,124
| -0.9% | -$12M | 0.02% | 628 |
|
|
2025
Q3 | $1.17B | Sell |
2,282,972
-107,651
| -5% | -$47M | 0.02% | 639 |
|
|
2025
Q2 | $750M | Sell |
2,390,623
-142,983
| -6% | -$42.9M | 0.01% | 811 |
|
|
2025
Q1 | $772M | Sell |
2,533,606
-37,164
| -1% | -$12.5M | 0.01% | 766 |
|
|
2024
Q4 | $854M | Buy |
2,570,770
+25,704
| +1% | +$8.72M | 0.01% | 748 |
|
|
2024
Q3 | $850M | Buy |
2,545,066
+17,309
| +0.7% | +$6.58M | 0.02% | 748 |
|
|
2024
Q2 | $1.04B | Buy |
2,527,757
+23,443
| +0.9% | +$9.28M | 0.02% | 624 |
|
|
2024
Q1 | $1.01B | Sell |
2,504,314
-52,129
| -2% | -$18.3M | 0.02% | 649 |
|
|
2023
Q4 | $784M | Buy |
2,556,443
+142,591
| +6% | +$38.5M | 0.02% | 723 |
|
|
2023
Q3 | $584M | Sell |
2,413,852
-48,331
| -2% | -$12.4M | 0.01% | 820 |
|
|
2023
Q2 | $591M | Sell |
2,462,183
-198,206
| -7% | -$41.2M | 0.01% | 832 |
|
|
2023
Q1 | $500M | Sell |
2,660,389
-35,757
| -1% | -$7.4M | 0.01% | 907 |
|
|
2022
Q4 | $573M | Sell |
2,696,146
-76,507
| -3% | -$15.3M | 0.02% | 798 |
|
|
2022
Q3 | $436M | Sell |
2,772,653
-224,399
| -7% | -$35.8M | 0.01% | 907 |
|
|
2022
Q2 | $449M | Sell |
2,997,052
-131,169
| -4% | -$19M | 0.01% | 927 |
|
|
2022
Q1 | $512M | Sell |
3,128,221
-40,998
| -1% | -$6.76M | 0.01% | 944 |
|
|
2021
Q4 | $690M | Buy |
3,169,219
+2,154
| +0.1% | +$451K | 0.02% | 815 |
|
|
2021
Q3 | $599M | Sell |
3,167,065
-60,738
| -2% | -$11.1M | 0.01% | 872 |
|
|
2021
Q2 | $570M | Sell |
3,227,803
-86,108
| -3% | -$14.9M | 0.01% | 911 |
|
|
2021
Q1 | $544M | Sell |
3,313,911
-23,302
| -0.7% | -$3.56M | 0.01% | 904 |
|
|
2020
Q4 | $465M | Buy |
3,337,213
+53,669
| +2% | +$6.76M | 0.01% | 920 |
|
|
2020
Q3 | $367M | Sell |
3,283,544
-350,340
| -10% | -$40.5M | 0.01% | 914 |
|
|
2020
Q2 | $338M | Sell |
3,633,884
-82,538
| -2% | -$7.02M | 0.01% | 953 |
|
|
2020
Q1 | $273M | Sell |
3,716,422
-47,057
| -1% | -$4.09M | 0.01% | 950 |
|
|
2019
Q4 | $316M | Buy |
3,763,479
+69,844
| +2% | +$5.41M | 0.01% | 1100 |
|
|
2019
Q3 | $310M | Buy |
3,693,635
+34,778
| +1% | +$2.63M | 0.01% | 1058 |
|
|
2019
Q2 | $239M | Buy |
3,658,857
+150,947
| +4% | +$8.7M | 0.01% | 1242 |
|
|
2019
Q1 | $207M | Buy |
3,507,910
+387,461
| +12% | +$23.1M | 0.01% | 1320 |
|
|
2018
Q4 | $165M | Buy |
3,120,449
+222,747
| +8% | +$12.2M | 0.01% | 1363 |
|
|
2018
Q3 | $174M | Buy |
2,897,702
+1,126,649
| +64% | +$61.6M | 0.01% | 1489 |
|
|
2018
Q2 | $76.2M | Buy |
1,771,053
+533,499
| +43% | +$21.6M | ﹤0.01% | 1908 |
|
|
2018
Q1 | $43.2M | Buy |
1,237,554
+43,594
| +4% | +$1.59M | ﹤0.01% | 2154 |
|
|
2017
Q4 | $43.3M | Buy |
1,193,960
+149,387
| +14% | +$5.24M | ﹤0.01% | 2131 |
|
|
2017
Q3 | $33.3M | Buy |
1,044,573
+30,134
| +3% | +$920K | ﹤0.01% | 2253 |
|
|
2017
Q2 | $29.4M | Buy |
1,014,439
+191,597
| +23% | +$5.37M | ﹤0.01% | 2287 |
|
|
2017
Q1 | $24.6M | Buy |
822,842
+90,742
| +12% | +$2.93M | ﹤0.01% | 2363 |
|
|
2016
Q4 | $26.4M | Buy |
732,100
+636,945
| +669% | +$21.2M | ﹤0.01% | 2295 |
|
|
2016
Q3 | $2.84M | Buy |
+95,155
| New | +$2.78M | ﹤0.01% | 3258 |
|
Other funds holding MEDP
WA
Vanguard Group's MEDP Position: Q4 2025 in Review
Vanguard Group reduced its Medpace (MEDP) stake by 0.93% in Q4 2025, selling an estimated $12M and leaving 2,261,848 shares worth $1.27B. The position accounts for 0.02% of the portfolio, ranked #628.
Vanguard Group first reported a position in MEDP in Q3 2016 and has held it in 38 quarters since. 785 funds tracked by Wall St. Rank hold MEDP as of Q4 2025.
- Vanguard Group held 2,261,848 shares of Medpace worth $1.27B as of Q4 2025.
- Vanguard Group sold 21,124 Medpace shares in Q4 2025, an estimated $12M.
- Medpace made up 0.02% of Vanguard Group's portfolio in Q4 2025, its #628 holding.
- Vanguard Group first reported a position in Medpace in Q3 2016 and has held it in 38 quarters since.
- 785 funds tracked by Wall St. Rank held Medpace as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.